An Interchangeable Biosimilars vs Authorized Biologics Battle May Be Looming





- Oct 22, 2021
AMCP Nexus 2021: A Wrap-Up


- Oct 21, 2021
AMCP Nexus 2021: Biosimilars Are Gathering Momentum — and Interchangeability May Not Matter


- Apr 20, 2021
Further Dissecting the Launch of Adalimumab Biosimilars in the US


- Apr 20, 2021
National Trends in Prescription Drug Expenditures and Projections for 2021


- Oct 8, 2020
EY Announces Howard Krass of IPD Analytics, LLC as Entrepreneur Of The Year® 2020 Winner


- May 15, 2020
Will COVID-19 Clog Generics, Biologics Pipeline?


- Apr 29, 2020
IPD Analytics Experts Discuss Humira's Influence on Biosimilars


- Apr 26, 2020
IPD Analytics Experts Discuss the Insulin Pipeline


- Apr 22, 2020
Drug Pipeline for 2020 Strong in Generics, Biosimilars


- Apr 20, 2020
A Look at the Generic and Biosimilar Drug Pipeline


- Apr 20, 2020
AMCP Presenters Predict 4 More Biosimilar Launches in 2020


- Jan 23, 2020
Express Scripts Coverage, FDA Label Update Boost Rybelsus


- Aug 12, 2019
Q&A, Part II: How Payers and Providers are Responding to the Biosimilar Market


- Aug 5, 2019
Q&A: What Providers Need to Know About a Changing Biosimilar Market


- Aug 1, 2019
National Trends in Prescription Drug Expenditures and Projections for 2019


- May 9, 2019
ICER, IPD Announce New Analytics Partnership